Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Seenu Hariprasad

Ophthalmology Chicago, IL Medical Doctor

NPI 1639235880 CMS profile 255365

5841 S Maryland Ave, Chicago, IL 60637

Open in the dashboard

General payments

$2,277,862

1,418 records reported · program years 2019–2025

Research payments

$7,525

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seenu Hariprasad of Chicago, IL is reported in the CMS Open Payments database as having received $2,277,862 across 1,418 general payments and $7,525 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $399,403 194
2025 Research $5,005 1
2024 General $313,712 198
2024 Research $2,520 3
2023 General $359,571 263
2022 General $342,249 229
2021 General $244,346 142
2020 General $207,622 105
2019 General $410,959 287

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seenu Hariprasad
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Seenu Hariprasad were reported at $399,403. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Seenu Hariprasad Ophthalmology median Middle half National median
2019 $410,959 $258 $104–$655 $163
2020 $207,622 $126 $45–$321 $114
2021 $244,346 $205 $76–$534 $132
2022 $342,249 $266 $100–$678 $149
2023 $359,571 $308 $117–$745 $160
2024 $313,712 $340 $127–$846 $164
2025 $399,403 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $739,711 528 payments
  2. Harrow Eye, LLC $203,364 46 payments
  3. Astellas Pharma US Inc $193,933 131 payments
  4. Novartis Pharmaceuticals Corporation $158,904 87 payments
  5. Allergan Inc. $146,173 136 payments
  6. AbbVie, Inc. $134,970 86 payments
  7. Biogen, Inc. $134,659 73 payments
  8. Alimera Sciences, Inc. $128,984 49 payments
  9. EyePoint Pharmaceuticals US, Inc. $120,502 78 payments
  10. Coherus Biosciences Inc. $78,790 43 payments
  11. Other $237,873 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,523,280 287 payments
  2. Consulting Fee $467,849 132 payments
  3. Honoraria $152,328 29 payments
  4. Travel and Lodging $101,497 500 payments
  5. Food and Beverage $32,908 470 payments
Products named General payments · program years 2019–2025
  1. EYLEA $503,468 360 payments
  2. EYLEA HD $284,560 210 payments
  3. IHEEZO $202,246 43 payments
  4. Izervay $181,536 124 payments
  5. TRIESENCE $176,859 33 payments
  6. OZURDEX $168,441 138 payments
  7. ILUVIEN $128,519 48 payments
  8. YUTIQ $120,443 76 payments
  9. BEOVU $91,827 47 payments
  10. Cimerli $78,790 43 payments
  11. Other $252,931 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $7,525 4 payments

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$125,913

Of which drugs: $2,623

Medicare patients

297

Average age 74

Services billed

1,612

177 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 49%
Chronic kidney disease 41%
Ischemic heart disease 35%
Heart failure 31%
Cancer 21%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bevacizumab, 10 mg J9035 Office 23 48 $2,623

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
$128,933 — —
Izervay
$82,603 — —
Cimerli
$45,073 — —
IHEEZO
$25,834 — —
EYLEA
$9,576 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

1,422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record